Cogent Biosciences’ (COGT) Neutral Rating Reiterated at Wedbush

Wedbush restated their neutral rating on shares of Cogent Biosciences (NASDAQ:COGT – Free Report) in a research note released on Tuesday,RTT News reports. They currently have a $11.00 target price on the technology company’s stock. Wedbush also issued estimates for Cogent Biosciences’ Q1 2025 earnings at ($0.44) EPS, Q2 2025 earnings at ($0.39) EPS, Q3 […]

Feb 28, 2025 - 08:57

Wedbush restated their neutral rating on shares of Cogent Biosciences (NASDAQ:COGT – Free Report) in a research note released on Tuesday,RTT News reports. They currently have a $11.00 target price on the technology company’s stock. Wedbush also issued estimates for Cogent Biosciences’ Q1 2025 earnings at ($0.44) EPS, Q2 2025 earnings at ($0.39) EPS, Q3 […]